Alkermes (ALKS) Liabilities and Shareholders Equity (2011 - 2026)

Alkermes (ALKS) reported Liabilities and Shareholders Equity of $4.3 billion for Q1 2026, up 104.52% year-over-year from $2.1 billion in Q1 2025, and up 71.21% quarter-over-quarter from $2.5 billion in Q4 2025.

Alkermes (ALKS) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $4.3 billion in Q1 2026.

  • Liabilities and Shareholders Equity for Q1 2026 came in at $4.3 billion, up 104.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.3 billion (up 33.27% YoY), and the FY2025 annual result was $2.5 billion, up 20.99% from the prior year.
  • Liabilities and Shareholders Equity improved to $4.3 billion in Q1 2026 per ALKS's latest filing, from $2.5 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $4.3 billion in Q1 2026 and troughed at $1.9 billion in Q1 2023.
  • A 5-year average of $2.3 billion and a median of $2.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity declined 5.44% in 2024, then soared 104.52% in 2026.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.0 billion in 2022, then climbed by 8.77% to $2.1 billion in 2023, then decreased by 3.78% to $2.1 billion in 2024, then rose by 20.99% to $2.5 billion in 2025, then jumped by 71.21% to $4.3 billion in 2026.
  • Business Quant data shows ALKS's Liabilities and Shareholders Equity at $4.3 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.3 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 40.04 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 15.15 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 6.71 Bn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 555.95 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 4.91 Bn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 13.22 Bn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 4.26 Bn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 2.35 Bn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn 2.27 Bn
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn 401.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.26 Bn
Dec 31, 2025 2.49 Bn
Sep 30, 2025 2.33 Bn
Jun 30, 2025 2.25 Bn
Mar 31, 2025 2.08 Bn
Dec 31, 2024 2.06 Bn
Sep 30, 2024 2.16 Bn
Jun 30, 2024 2.21 Bn
Mar 31, 2024 2.12 Bn
Dec 31, 2023 2.14 Bn
Sep 30, 2023 2.28 Bn
Jun 30, 2023 2.19 Bn
Mar 31, 2023 1.92 Bn
Dec 31, 2022 1.96 Bn
Sep 30, 2022 1.94 Bn
Jun 30, 2022 1.96 Bn
Mar 31, 2022 1.98 Bn
Dec 31, 2021 2.02 Bn
Sep 30, 2021 2.00 Bn
Jun 30, 2021 1.94 Bn